What Happened?
Hasbrouck Heights, NJ-based Nymox Appointed Paul Averback as Chief Executive Officer
About the Company
NYMOZARFEX (TM) is given in an in-office procedure that is administered in a few minutes without need of anesthesia or analgesia. The drug has been tested in clinical trials involving overall more than 1750 patients with over 1600 injections administered including over 1200 Fexapotide administrations. Fexapotide has led to significant long-term improvements and has shown an excellent safety profile without the side effects normally associated with existing BPH treatments.
About the Person
Paul Averback is Chief Executive Officer at Nymox. Previously, Paul held various senior HR leadership roles in the industry.
Info Source
News
Short Profile